Drugs / CaEDTA
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06016088 | Apr 2024 → Apr 2026 | Pseudomonas aeruginosa infectious disease, cystic fibrosis, respiratory tract infectious disorder | Respirion Pharmaceuticals Pty Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06811233 | May 2025 → Aug 2029 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ca-EDTA | “Each dose of RSP-1502 contains the active components tobramycin (300 mg) and CaEDTA in a 5 mL solution.” NCT06016088 ↗ |
| Route | Inhaled | “RSP-1502 is a sterile, preservative free solution to be administered by inhalation via a nebulizer.” NCT06016088 ↗ |